Back to top

vaccines: Archive

Zacks Equity Research

MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine

Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.

SNYPositive Net Change GSKPositive Net Change MRNAPositive Net Change

Sundeep Ganoria

3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains

Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.

JNJPositive Net Change MRKNegative Net Change ABBVPositive Net Change

Zacks Equity Research

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise

SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.

SNYPositive Net Change DVAXNegative Net Change CRMDPositive Net Change CSTLPositive Net Change

Sundeep Ganoria

ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?

AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.

AZNPositive Net Change ABBVPositive Net Change

Sundeep Ganoria

Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?

PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.

PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change SMMTPositive Net Change

Zacks Equity Research

CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike

CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.

MRNAPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change